SubscribeLatest 5 articles from heartwire
- Sen Grassley questions top medical schools about ghostwriting
Nov 20, 2009 13:15 EDT - Stroke incidence related to PCI steady over 15 years
Nov 20, 2009 13:00 EDT - ALLHAT investigators report 10-year follow-up and stand by diuretics as first step antihypertensive treatment
Nov 19, 2009 14:00 EDT - Oral anticoagulants REDEEMed? Daily dabigatran "safe" with dual antiplatelets after MI
Nov 19, 2009 11:00 EDT - EFFECT: Public reporting of hospital performance improves quality of care?
Nov 19, 2009 10:00 EDT
Rosuvastatin in the prevention of venous thromboembolism
Posted May 29, 2009
at 11:45 AM, EDT
by Samuel Goldhaber
What are the implications of the JUPITER trial's landmark findings in preventing venous thromboembolism? A 43% highly significant reduction in incidence and no increased bleeding risk with rosuvastatin 20 mg daily compared with placebo. Where do we go next? And what do we do now in clinical practice?
Please refer to the epublished JUPITER manuscript: Glynn RJ et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; March 29.
Posted by A G G Turpie, Aug 12, 2009
Publié le A G G Turpie, 08.12.2009
Previous postsBillets précédents
Epidemiology of pulmonary embolism in the US
No commentsAucun commentaire |
Posted Nov 04, 2009
at 02:00 PM, EDT by Samuel Publié le 11.04.2009 à 14h00 par Samuel
at 02:00 PM, EDT by Samuel Publié le 11.04.2009 à 14h00 par Samuel
CURRENT OASIS-7: Doubling the clopidogrel dose in ACS patients undergoing PCI
1 comment1 commentaire |
Posted Oct 22, 2009
at 09:30 AM, EDT by Samuel Publié le 10.22.2009 à 09h30 par Samuel
at 09:30 AM, EDT by Samuel Publié le 10.22.2009 à 09h30 par Samuel
Support groups for pulmonary embolism patients
No commentsAucun commentaire |
Posted Aug 14, 2009
at 10:45 AM, EDT by Samuel Publié le 08.14.2009 à 10h45 par Samuel
at 10:45 AM, EDT by Samuel Publié le 08.14.2009 à 10h45 par Samuel
Graduated compression stockings and VTE prevention in stroke patients
No commentsAucun commentaire |
Posted Jul 20, 2009
at 10:30 AM, EDT by Samuel Publié le 07.20.2009 à 10h30 par Samuel
at 10:30 AM, EDT by Samuel Publié le 07.20.2009 à 10h30 par Samuel
Clot is hot at ISTH
No commentsAucun commentaire |
Posted Jul 14, 2009
at 12:00 AM, EDT by Samuel Publié le 07.14.2009 à 00h00 par Samuel
at 12:00 AM, EDT by Samuel Publié le 07.14.2009 à 00h00 par Samuel
Also from theheart.org
Blogs I read
Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
CommentsCommentaires
Given that there are a plethora of statin trials that have already been conducted, it would seem that, even though VTE may not have been a prespecified endpoint, one could go back to these databases and determine whether similar reductions in VTE were demonstrated versus placebo.
Der Dr Goldhaber,
DVT is a real threat as we know but this is the first time that we have discovered the statins to have a bearing on it.Congratulations to you from India!
Dr Sadasivan.
the Virchow triad:
thrombosis is due to three factors-stasis
-hypercoaguabilité
-hyperviscosity
when you give a cause neuroleptic you demunition stasis by the seimulation nerve in vascular
so it always involve a antiagréguant or heparin with neuroleptics